Sanofi Executive Calls for Fundamental Shift in Clinical Trial Supply Models Amid Rising Market Pressures
核心洞察
Arnaud Dourlens, Sanofi's head of clinical supply chain operations, highlights that traditional clinical trial supply (搜索) models must evolve to handle increased variability and complexity in the current pharmaceutical landscape.
The pharmaceutical industry faces unprecedented challenges including 80% of clinical trials failing to meet enrollment targets, increased competition, and geopolitical risks requiring more resilient supply chain approaches.
Future supply models must balance efficiency with resilience through digitalization, AI integration, and enhanced collaboration between clinical teams and supply chain operations to ensure patient access and operational success.
The pharmaceutical industry's clinical trial supply (搜索) chains are at a critical inflection point, requiring fundamental transformation to address mounting pressures from market competition, regulatory complexity, and geopolitical uncertainty, according to Arnaud Dourlens, head of clinical supply chain operations at Sanofi.
Speaking at the Clinical Trial Supply (搜索) conference in Barcelona in February 2026, Dourlens outlined how traditional supply models built for predictable environments are increasingly inadequate for today's volatile landscape. Research indicates that up to 80% of clinical trials fail to meet their enrollment targets, making conventional forecasting approaches unreliable and necessitating more adaptive supply strategies.
Market Dynamics Drive Supply Chain Evolution
The clinical trials ecosystem has undergone dramatic shifts in recent years, with higher concentration and competition among pharmaceutical companies increasingly targeting similar disease areas and patient populations. This convergence has led to an explosion in the total number of clinical trials while simultaneously compressing competitive timelines.
"The level of competition in similar indications is leading to a paradigm in which new competitors arrive with a clinical trial that may compete directly with the asset someone put on the market within two to three years, whereas this was more like eight to 10 years in the 1990s," Dourlens explained.
These market pressures coincide with an explosion in R&D costs, creating a challenging environment where commercial benefits are eroding while scrutiny around risk management intensifies. The result is increased pressure on clinical supply chains with less room for errors and more demanding requirements for operational flexibility.
Technology and Data Integration as Critical Enablers
Dourlens emphasized that digitalization plays a key role in connecting various data sources to provide real-time visibility across supply networks. However, he noted that while abundant data exists, it is often poorly qualified, undefined, or inaccessible.
"Leadership needs to evolve to cross boundaries and be able to interact with all stakeholders in the clinical supply ecosystem, meaning the vendors and different internal stakeholders at the pharma level, to be able to connect all datasets and data points," he said.
The integration of artificial intelligence represents the second critical advancement, enabling rapid identification of previously missed signals and translating them into actionable insights for demand shifts, risks, or network threats. However, Dourlens cautioned that without proper data foundation, AI implementation will provide only limited benefits.
Geopolitical Risks Reshape Supply Strategies
Global policy unpredictability and geopolitical fragmentation are forcing pharmaceutical companies to reconsider centralized supply models. Dourlens cited Germany's recent pricing policy evolution, which offers price bonuses for drugs where more than 5% of clinical patients are German, as an example of how rapidly changing regulatory landscapes can impact trial strategies.
"Given the level of risk and exposure we have, between the conflict in different countries and the potential for major disruption around international logistics, we also need to think differently about the wisdom of centralized supply models," Dourlens noted.
This environment necessitates a fundamental shift from efficiency-focused models toward approaches that balance efficiency with resilience. Future success will depend on maintaining operational continuity regardless of global disruptions through diversified regional partnerships and enhanced risk mapping capabilities.
Collaborative Integration Between Clinical and Supply Teams
Perhaps the most significant transformation needed involves breaking down silos between clinical teams and supply chain operations. Dourlens argued that the traditional model of pushing product flow based on forecasts is no longer suitable given current enrollment variability.
"We ultimately need more sharing and common understanding between the clinical teams and the clinical supply chain teams. At the end of the day, we are working with the same information," he emphasized.
This integration requires working with shared datasets and systems to achieve optimal balance between smooth operations and timely risk management, ultimately benefiting patients and ecosystem stakeholders.
The evolution toward more adaptive, technology-enabled supply models represents a critical strategic imperative as the pharmaceutical industry navigates an increasingly complex and competitive landscape. Companies that successfully balance efficiency with resilience while leveraging advanced analytics and collaborative approaches will be best positioned to maintain operational excellence in this challenging environment.